Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMNGT89)

Drug Name
Lirilumab Drug Info
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 2 [1]
Chronic lymphocytic leukaemia 2A82.0 Phase 2 [2]
Myelodysplastic syndrome 2A37 Phase 2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [3]
Cross-matching ID
TTD Drug ID
DMNGT89

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
RAS-like protein KIR (GEM) TTAZF9M GEM_HUMAN Modulator [4]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
RAS-like protein KIR (GEM) DTT GEM 6.849 8.679 5.902 7.337
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Acute myeloid leukaemia
ICD Disease Classification 2A60
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
RAS-like protein KIR (GEM) DTT GEM 4.29E-04 0.06 0.1
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02481297) Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a preclinical xenograft tumor model. J Immunother Cancer. 2013; 1(Suppl 1): P40.